Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B.
Document Type
Article
Publication Date
9-15-2018
Publication Title
Journal of immunology (Baltimore, Md. : 1950)
Abstract
Glatiramer acetate (GA; Copaxone) is a copolymer therapeutic that is approved by the Food and Drug Administration for the relapsing-remitting form of multiple sclerosis. Despite an unclear mechanism of action, studies have shown that GA promotes protective Th2 immunity and stimulates release of cytokines that suppress autoimmunity. In this study, we demonstrate that GA interacts with murine paired Ig-like receptor B (PIR-B) on myeloid-derived suppressor cells and suppresses the STAT1/NF-κB pathways while promoting IL-10/TGF-β cytokine release. In inflammatory bowel disease models, GA enhanced myeloid-derived suppressor cell-dependent CD4
Clinical Institute
Cancer
Department
Oncology
Department
Earle A. Chiles Research Institute
Recommended Citation
van der Touw, William; Kang, Kyeongah; Luan, Yi; Ma, Ge; Mai, Sunny; Qin, Lihui; Bian, Guanglin; Zhang, Ruihua; Mungamuri, Sathish Kumar; Hu, Hong-Ming; Zhang, Cheng Cheng; Aaronson, Stuart A; Feldmann, Marc; Yang, Wen-Chin; Chen, Shu-Hsia; and Pan, Ping-Ying, "Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B." (2018). Articles, Abstracts, and Reports. 665.
https://digitalcommons.providence.org/publications/665
